Rezolute, Inc. (RZLT)
NASDAQ: RZLT · Real-Time Price · USD
5.68
+0.05 (0.89%)
At close: Oct 29, 2024, 4:00 PM
5.73
+0.05 (0.88%)
After-hours: Oct 29, 2024, 5:38 PM EDT
Company Description
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.
The company’s lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema.
The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.
Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Rezolute, Inc.
| Country | United States |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 51 |
| CEO | Nevan Elam |
Contact Details
Address: 275 Shoreline Drive, Suite 500 Redwood City, California 94065 United States | |
| Phone | 650 206 4507 |
| Website | rezolutebio.com |
Stock Details
| Ticker Symbol | RZLT |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001509261 |
| CUSIP Number | 76200L309 |
| ISIN Number | US76200L3096 |
| Employer ID | 27-3440894 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Davelyn Eaves Hood M.B.A., M.D. | Director and Head of Scientific and Patient Affairs |
| Michael R. Deperro | Senior Vice President and Head of Corporate Development |
| Michael Covarrubias | Senior Vice President and Head of Program & Portfolio Management |
| Chris Milks | Vice President and Head of Finance |
| Dr. Raj Agrawal M.D. | Vice President and Head of Ophthalmological Clinical Development |
| Robyn Sweinhart | Vice President and Head of Quality |
| Erin O'Boyle | Senior Vice President and Head of Clinical Operations |
| Susan Stewart J.D., L.L.M. | Chief Regulatory Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 21, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 21, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 10, 2024 | PRE 14A | Other preliminary proxy statements |
| Sep 19, 2024 | 10-K | Annual Report |
| Sep 19, 2024 | 8-K | Current Report |
| Sep 9, 2024 | 8-K | Current Report |
| Aug 14, 2024 | EFFECT | Notice of Effectiveness |
| Aug 12, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Aug 9, 2024 | UPLOAD | Filing |
| Aug 5, 2024 | S-3 | Registration statement under Securities Act of 1933 |